EPICS Therapeutics Announces First Cohort Dosed with EP102 in First-In-Patient Oncology Trial and Securement of Additional Financing

Gosselies, Belgium - September 22nd,…

Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer.

January 12th, 2022 – Epics…